Overview
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare subtype of hepatocellular carcinoma (HCC) predominantly affecting young adults without underlying liver disease. Characterized by a distinct histological appearance featuring a unique eosinophilic fibrous stroma, FL-HCC exhibits unique molecular underpinnings compared to conventional HCC. Understanding the specific molecular mechanisms driving FL-HCC is crucial for developing targeted therapies and improving patient outcomes. Recent research has highlighted the roles of FOXM1 degradation via P49-PROTACVHL and UXS1 overexpression in the pathogenesis and potential therapeutic targets for this malignancy [PMID:42094592, PMID:41843361].
Pathophysiology
The pathophysiology of fibrolamellar HCC involves intricate molecular interactions that distinguish it from other forms of HCC. One key mechanism involves the P49-PROTACVHL compound, which recruits FOXM1 to the VHL E3 ligase complex, leading to FOXM1 degradation. This process is pivotal as it attenuates both fibrosis and hepatocarcinogenesis in mouse models [PMID:42094592]. The degradation of FOXM1, a transcription factor critical for cell cycle progression and proliferation, disrupts pathways essential for tumor growth and survival. Consequently, targeting FOXM1 with PROTACs (Proteolysis Targeting Chimeras) represents a promising therapeutic strategy to mitigate the aggressive nature of FL-HCC.
Additionally, the overexpression of UXS1 (Ufm1 Specific Protease 1) has emerged as another critical factor in FL-HCC progression. Studies have shown that UXS1 mRNA levels are significantly elevated in HCC tissues and correlate with poorer overall and progression-free survival rates [PMID:41843361]. Mechanistically, UXS1 knockdown induces ferroptosis, a form of programmed cell death characterized by iron-dependent lipid peroxidation. This induction occurs through the disruption of reactive oxygen species (ROS) homeostasis and downregulation of anti-ferroptotic proteins such as GPX4 (glutathione peroxidase 4) and SLC7A11 (solute carrier family 7 member 11). These findings suggest that UXS1 could serve as a therapeutic target, as inhibiting its function may suppress HCC cell proliferation, migration, and invasion, thereby offering a novel avenue for treatment.
Diagnosis
Diagnosing fibrolamellar HCC typically involves a combination of clinical presentation, imaging studies, and histopathological examination. Patients often present with nonspecific symptoms such as abdominal pain, weight loss, and jaundice, which can complicate early detection. Imaging modalities like computed tomography (CT) scans and magnetic resonance imaging (MRI) are crucial for identifying characteristic features such as a large, solitary tumor with a distinctive fibrous stroma. However, definitive diagnosis relies on liver biopsy and histopathological analysis, where the hallmark features include the presence of eosinophilic fibrous septa and a lack of significant background liver disease [PMID:42094592]. Given the rarity and distinct nature of FL-HCC, pathologists should maintain a high index of suspicion for this diagnosis, especially in young patients without known risk factors for liver disease.
Management
Current Therapeutic Approaches
The management of fibrolamellar HCC remains challenging due to its aggressive nature and rarity. Recent clinical trials have explored various therapeutic strategies, with notable emphasis on immunotherapy and targeted molecular approaches. In a phase II trial [PMID:42047833], the combination of ociperlimab (an anti-PD-1 antibody), tislelizumab (another anti-PD-1 antibody), and BAT1706 (a Bcl-2 inhibitor) demonstrated promising results. Patients treated with this triplet regimen (Arm A) achieved an objective response rate (ORR) of 37.1%, slightly lower than those treated with tislelizumab and BAT1706 alone (Arm B) at 40.6%. Despite these differences, both arms showed significant clinical activity, highlighting the potential of immunotherapy combinations in treating advanced FL-HCC.
Adverse events were common across both treatment arms, with 90.3% and 80.6% of patients in Arms A and B, respectively, experiencing treatment-related adverse events. Grade ≥3 adverse events were reported in 59.7% and 32.3% of patients in Arms A and B, respectively, with immune-mediated adverse events affecting 50.0% and 45.2% of patients, respectively. These findings underscore the importance of close monitoring and supportive care in managing these toxicities.
Emerging Therapeutic Targets
Preclinical studies have provided insights into potential targeted therapies that could revolutionize the treatment landscape for FL-HCC. The use of P49-PROTACVHL to degrade FOXM1 has shown significant promise in mitigating liver fibrosis and suppressing tumor progression in animal models [PMID:42094592]. This approach not only targets the tumor directly but also addresses the fibrotic component characteristic of FL-HCC, potentially leading to improved long-term outcomes. Translating these findings into clinical settings could offer a dual benefit by reducing both tumor burden and associated fibrosis.
Furthermore, targeting UXS1 represents another promising avenue. Given that UXS1 knockdown induces ferroptosis, which effectively halts HCC cell proliferation and invasion, therapeutic strategies aimed at inhibiting UXS1 could be highly efficacious [PMID:41843361]. Developing specific inhibitors or leveraging existing agents that can modulate UXS1 activity might provide a novel therapeutic strategy to combat FL-HCC, particularly in patients with high UXS1 expression, which correlates with poorer prognosis.
Prognosis & Follow-up
The prognosis of fibrolamellar HCC is generally poor, often characterized by rapid progression and limited response to conventional treatments. However, emerging therapeutic strategies offer hope for improved outcomes. Targeting FOXM1 with PROTACs like P49-PROTACVHL could potentially enhance long-term survival by simultaneously addressing both tumor growth and fibrosis [PMID:42094592]. Clinical trials such as the one mentioned [PMID:42047833] have shown objective response rates of up to 40.6% with immunotherapy combinations, suggesting that these approaches might positively impact patient prognosis, particularly in first-line therapy settings.
High UXS1 expression in HCC tissues serves as a robust prognostic biomarker, consistently correlating with poorer overall and progression-free survival [PMID:41843361]. Monitoring UXS1 levels could help stratify patients into risk categories, guiding more personalized treatment strategies. Post-treatment follow-up should include regular imaging studies (such as CT or MRI) and biomarker assessments to detect early signs of recurrence or treatment resistance. Additionally, clinical vigilance for immune-related adverse events remains crucial, given the reliance on immunotherapy in current treatment regimens.
Key Recommendations
These recommendations aim to leverage current evidence while acknowledging the evolving nature of FL-HCC management, emphasizing the need for ongoing research and clinical trials to refine therapeutic approaches.
References
1 Wu D, Duan L, Tan D, Hua X, Liang A, Huai R et al.. A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis. Theranostics 2026. link 2 Ren Z, Huang Y, Guo Y, Hou MM, Wang W, Kuang M et al.. AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. Cancer immunology, immunotherapy : CII 2026. link 3 Lv J, Han K, Gan FY, Li MH, Yin QJ. UXS1 Knockdown Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma by Inducing Ferroptosis via SLC7A11/GPX4 Pathway. Current medical science 2026. link